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Purpose: Noonan syndrome (NS) is a genetic disorder that is associated with social cognitive 
problems. While treatment aimed at the improvement of social cognition is available for other 
neuropsychiatric disorders, no such interventions yet exist for NS patients. In this study, the 
development of the first social cognitive training for NS patients is described and its applicability 
and feasibility evaluated.
Methods: Eleven adult patients with NS participated in this controlled proof-of-principle study. 
Six patients were included in the treatment group and five in the control group. Neuropsychologi-
cal testing was performed in both groups at baseline and posttreatment. Social cognition was 
a primary outcome measure and nonsocial cognition and psychopathology secondary outcome 
measures. Differences between pre- and posttest were investigated with Wilcoxon signed-rank 
tests, and a process evaluation was performed to aid interpretation of the results.
Results: Both groups were comparable with regard to age, estimated intelligence, and baseline 
performance. Although no significant differences were found between pre- and posttest scores 
on primary and secondary outcome measures in either group, a medium–large effect size was 
found on emotion recognition in the treatment group. Also, the process evaluation demonstrated 
the feasibility of the training.
Conclusion: This first social cognitive training for adult patients with NS has proven to be 
feasible for this population and showed some encouraging results regarding emotion recogni-
tion, although the training protocol could be optimized. Further investigation is required using 
a randomized controlled design in a larger sample, in order to substantiate the overall effective-
ness of the training.
Keywords: social cognition, alexithymia, cognition, social cognitive intervention, genetic 
syndrome
Introduction
Noonan syndrome (NS) is an autosomal-dominant genetic disorder characterized by 
distinctive facial features, congenital heart disease, short stature, and varying degrees 
of developmental delay. Other features include chest deformities, a broad or webbed 
neck, cryptorchidism, coagulation defects, and lymphatic dysplasia.1,2 The estimated 
prevalence is one in 1,000–2,500 live births.3 NS is caused by germ-line mutations 
encoding components of the Ras–MAPK pathway, a signal-transduction cascade 
involved in several developmental processes, such as cell-cycle regulation, differentia-
tion, growth, apoptosis, and cell senescence.2,4 NS is one of the “RASopathies”, refer-
ring to a class of related developmental disorders that are caused by gene mutations, 
resulting in dysregulation of the Ras–MAPK pathway.5 To date, mutations in 17 genes 
have been associated with NS, of which those in PTPN11 (50%), SOS1 (10%), and 
RAF1 (10%) are most frequently identified.6 In approximately 75% of patients with NS, 
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a genetic mutation can be identified, although diagnosis is 
still primarily based on clinical criteria.7–9
In children with NS, difficulties have been found in 
several cognitive domains, ie, language, motor function, 
attention, executive function, and social cognition.10 Regard-
ing the cognitive profile of adults with NS, (low) average 
intelligence and lowered speed of information processing 
were found in comparison to matched controls.11 Performance 
on other cognitive domains, such as memory, executive 
functioning, and visuoconstruction, seems to be relatively 
intact in adulthood, although patients report subjective 
executive problems.11 With regard to social cognition – the 
mental processes underlying social functioning12 – in adults 
with NS, difficulty in identifying and describing one’s own 
emotional feelings (ie, higher levels of alexithymia), slight 
overall problems in facial emotion recognition and social dis-
comfort have been described.13 Alexithymia (from Greek for 
‘no words for emotions’) is a dimensional personality trait, 
reflecting weaknesses in cognitive processing and regulation 
of one’s own emotions. Alexithymia is characterized by dif-
ficulties in identifying and describing feelings, limited ima-
ginal capacity, and an externally oriented cognitive style.20 
In a variety of clinical and healthy populations, alexithymia 
has been related to social cognitive impairments, such as 
problems in the automatic processing of emotional stimuli, 
affect recognition, empathy, and mentalizing.65–76 Studies 
on a behavioral level in patients with NS showed higher 
prevalence of autism traits and weaker social skills, although 
it should be noted that these studies focused predominantly 
on children and only two included a (normally developing) 
control group.14–17 Even though only a few studies have inves-
tigated the presence of psychiatric disorders in adults with 
NS, mood and anxiety problems are suggested to be rather 
frequent.3,18,19 Despite the mental health risks associated with 
social cognitive impairments and alexithymia,12,20 no social 
cognitive intervention incorporating alexithymia training is 
yet available for patients with NS.
Various social cognitive interventions have demonstrated 
improvements in social cognition in adult neuropsychiatric 
patients (ie, patients with schizophrenia-spectrum disorders, 
autism-spectrum disorders, and acquired brain injury).21 
These treatments included targeted interventions, focusing 
on one social cognitive subdomain, eg, emotion recogni-
tion or theory of mind (ToM), comprehensive interventions 
that addressed more than one social cognitive subdomain, 
eg, emotion recognition and ToM training, and broad-
based interventions in which social cognition training was 
embedded in the context of other interventions, such as 
neurocognitive remediation or social skill training. In general, 
these social cognitive interventions were most effective in 
improving emotion perception, but ToM, social perception, 
and social functioning could also be trained effectively. 
Training of emotion perception appears to be an important 
component of effective social cognitive interventions, 
while addressing social functioning and providing suf-
ficient practice opportunities in daily life are beneficial 
for generalization.21 Some well-described social cognitive 
interventions for various neuropsychiatric disorders include 
social cognition and interaction training,22 treatment of affect 
recognition,23 cognitive enhancement therapy,24 and treatment 
for impairments in social cognition and emotion regulation.25 
Several social cognitive interventions exist for children with 
autism-spectrum disorder, but well-studied treatments for 
adults are scarce, although results seem promising.21,26 Given 
the fact that alexithymia is related to social cognitive dif-
ficulties, it is remarkable that social cognitive interventions 
for neuropsychiatric disorders do not address alexithymia.
Almost four decades ago, Krystal27 recommended the use 
of specific therapeutic techniques in alexithymic patients, 
such as making patients aware of their alexithymic problems 
and emotional feelings, developing affect tolerance, and 
providing psychoeducation regarding emotions (ie, their 
signal function, duration, and intensity), and helping patients 
to recognize and verbalize their emotions. A more recent 
narrative review on psychological interventions aimed at 
reducing alexithymia in psychiatric, medical, and healthy 
populations suggests that alexithymia is partly modifiable 
and that reductions in alexithymia scores can be obtained 
when alexithymia is directly trained.28 Some studies have 
used relaxation techniques and mindfulness to diminish 
stress levels and increase awareness of inner experiences and 
physical sensations.29–31 Psychoeducation regarding emotions 
and their function, as well as the identification of antecedents 
of alexithymia (eg, emotional expression in family of origin), 
have also been described.30–32 Since alexithymia is correlated 
with decrements in emotion recognition, many alexithymia 
interventions incorporate training of emotion perception, 
identification, and differentiation.29–33 Mentalizing and dif-
ferentiating bodily feelings, thoughts, emotions, and behavior 
have also been addressed.31,32 In order to improve verbaliza-
tion of emotions, training affect labeling, extension of the 
“emotional vocabulary”, and training of self-expression skills 
are used.31–33 Listening to music, creating fantasy stories, 
creative writing, noting dreams, reading literary fiction, or 
creating poetry can stimulate fantasizing.29,34 Lastly, Taylor 
and Bagby20 suggested that alexithymia interventions are 
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preferably provided in a group-therapy setting, because a 
group offers relevant interpersonal practice. However, they 
suggest that the groups should be small and consist of no 
more than three patients.
Because the existing social cognitive treatments do not 
incorporate alexithymia training, they are not completely suit-
able for NS patients, in whom specific difficulties in the iden-
tification and verbalization of their own emotions have been 
demonstrated. For this reason, a social cognitive training was 
developed, based on the promising results of previous social 
cognitive and alexithymia interventions and tailored to the 
specific (social) cognitive profile of adult patients with NS. 
The training consists of ten weekly group sessions comprising 
the three phases of social cognition: perception of one’s 
own emotions and the emotions of others, interpretation and 
integration of socially relevant information, and execution 
and regulation of social behavior.35 In this proof-of-principle 
study, the development, applicability, and feasibility of the 
new training protocol will be described in a group of patients 
with NS in comparison to an NS control group. Social cogni-
tion, operationalized by the three aforementioned phases of 
affective information processing, was a primary outcome 
measure. Given the cognitive profile of patients with NS and 
relation with social cognition, nonsocial cognition (speed 
of information processing, inhibition, planning abilities), 
psychopathology ([social] anxiety, depression), quality of 
life, and self-efficacy were the secondary outcome measures.
Methods
Design and procedure
Pilot sessions of the training were held at meetings of the 
Dutch Noonan Syndrome Foundation to investigate both 
interest and support for a social cognitive training, as well 
as to obtain input from patients and their relatives regarding 
important aspects of everyday functioning, eg, inclusion 
of training partners. Subsequently, a training protocol was 
designed by RR and EW, including important elements of 
evidence-based social cognitive interventions (eg, training 
of emotion recognition, ToM, social behavior) and exercises 
from alexithymia treatments. This resulted in a structured, 
10-week group intervention of 90-minute sessions in which 
the three phases of social cognition were addressed (per-
ception, interpretation, and reaction). The training protocol 
included psychoeducation and in-session exercises, incorpo-
rating emotion-recognition training, ToM and mentalizing 
strategies, and exercises to improve identification, labeling, 
and expression of (own) emotional feelings (see Table 1 for 
topics and content per session). Participants also performed 
homework exercises aimed at increasing awareness of one’s 
own emotional feelings and social behavior and allowed 
them to practice with the training topics. Each training 
session was structured similarly, starting with the evalua-
tion of homework exercises, psychoeducation concerning 
a social cognitive phase and/or subdomain, practice in the 
group, and introducing new homework. The group size was 
intentionally limited, with a maximum of five patients per 
group. Participants were asked to select a training partner, 
who was invited for two training sessions and performed 
homework exercises with the patients, in order to provide 
practice opportunities in daily life.
The current study had a controlled pre- vs posttest within-
subject design with a treatment group and a control group. 
Patients in the control group received treatment as usual 
(eg, psycho-education, psychological counseling, consulta-
tion with general practitioner and/or medical specialist). 
Before and after training, a neuropsychological test battery, 
including several (social) cognitive tasks and self-report 
questionnaires, was administered in both groups. The primary 
outcome measures reflected all three phases of affective 
information processing, thus including emotion recognition, 
ToM, social perception, alexithymia, and social behavioral 
problems. As secondary outcome measures, subjective and 
objective measures of nonsocial cognition, psychopathol-
ogy, quality of life, and self-efficacy were included. Proxies 
of patients in the treatment group were asked to complete 
two questionnaires as well. Training sessions were held at a 
central location in the Netherlands within an acceptable travel 
distance for all participants. For patients in the treatment 
group, pre- and posttests were planned at the same location 
and combined with the first and the last training session, if 
possible. Participants in the control group were tested at a 
location of their preference. However, most testing took place 
at the same location as for the treatment group and at about 
the same time. Control participants received a gift voucher as 
compensation for their travel expenses. Further information 
regarding the procedure is provided in the process analysis 
in Table 2.
Participants
Eleven patients with NS participated in this study. Four more 
patients were eligible for inclusion, but did not participate, 
due to current work or study obligations or nonresponse. Due 
to the small number of patients who volunteered to participate 
in the training study, it was not possible to allocate patients 
randomly to the treatment and control conditions. The 
treatment group consisted of six patients, who followed the 
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training in two consecutive groups. The control group com-
prised five patients. Participants were recruited by the Centre 
of Excellence for Neuropsychiatry of Vincent van Gogh 
Institute for Psychiatry, the Department of Medical Genetics 
of Radboud University Medical Center, Nijmegen, and the 
Dutch Noonan Syndrome Foundation. Written informed 
consent was obtained, and the study was approved by the 
Institutional Review Board of Vincent van Gogh Institute for 
Psychiatry, in accordance with the Declaration of Helsinki.
Inclusion criteria were a confirmed clinical diagnosis 
of NS or other RASopathy, minimum age of 16 years, and 
sufficient verbal capacities estimated during the intake 
procedure by two neuropsychologists (RR and EW). The 
presence of subjective or objective social cognitive impair-
ments was required for participation in the treatment group. 
More information regarding the recruitment and inclusion 
procedures is presented in Table 2.
The mean age in the treatment group was 47.7 years 
(SD 12.8, range 29–60) and 35.8 years in the control group 
(SD 9.8, range 23–46). Mean IQ, estimated by the Dutch 
version of the National Adult Reading Test (NART),36 was 
85.33 in the treatment group (SD 17.86, range 69–113) 
and 83.40 (SD 17.59, range 55–103) in the control group. 
Education level, according to the Dutch educational system 
and ranging from category 1 (,6 years of primary education) 
to 7 (academic degree),37 varied from 3 to 7 in the treatment 
group (mode 4) and from 2 to 5 in the control group (mode 5). 
In the treatment group, 17% of the participants were men, 
while in the control group 60% men were included. Half 
the participants in the treatment group had a mutation in the 
PTPN11 gene compared to 40% in the control group. One 
patient in the treatment group was diagnosed with NS with 
multiple lentigines and one patient in the control group with 
NS with loose anagen hair. After a Mann–Whitney U test, 
Table 1 Overview of topic and content of each training session
Session Topic Content
1 introduction Identification of treatment aims
Psychoeducation on social cognition (perception, interpretation, and reaction) in Ns
relaxation exercise
Perception
2 emotion perception in other 
people
Psychoeducation on emotions and emotion perception in others
exercises aimed at emotion perception via different modalities
3 Perception of own emotions introduction of emotion word of the day (repeated exercise)
Psychoeducation on (affective) alexithymia
Exercises regarding the identification of emotional feelings and mindfulness
4 Training partner session 
(with patients)
Psychoeducation on social cognition (in Ns)
Providing information regarding the training and the role of training partners
Interpretation
5 Theory of mind/perspective taking Psychoeducation on analyzing emotions, mentalizing, theory of mind, and perception of social 
information
exercises aimed at the perception of social faux pas, perspective taking, and social context
6 Theory of mind/perspective taking Psychoeducation on perspective taking and attributional biases
exercises concerning perspective taking, theory of mind, attributional biases, and social faux pas
Reaction
7 alexithymia Psychoeducation on (cognitive) alexithymia, emotion regulation, and inhibition
exchanging emotion-regulation strategies (coping with emotions) in family of origin
exercises aimed at extending the emotional vocabulary and alternative ways of expressing 
emotions
8 alexithymia Psychoeducation on coping strategies (reappraisal, acceptance, and action)
exercises regarding emotional expression
9 recapitulation summary of training information
evaluation of individual treatment aims
exercises concerning emotional expression and repeating exercises from previous phases
10 evaluation with training partners 
and patients
summary of training information
evaluation of individual mood boards (personal, nonverbal expression of the six basic emotions)
evaluating the role of training partners and treatment aims
Abbreviation: Ns, Noonan syndrome.
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Table 2 results from the process analysis organized as per process-evaluation components, related process measures, and process 
variables
Process components Findings
Study population 1. Recruitment and selection rate
1a. Number of eligible persons in screened population
Fifty-five patients from the Department of Clinical Genetics of Radboud University Medical Center and all contributors 
to the Dutch Noonan syndrome Foundation were contacted by letter or email with information regarding the training. 
This information was also displayed on the websites of the centre of excellence for Neuropsychiatry of the Vincent 
van gogh institute for Psychiatry and the Dutch Noonan syndrome Foundation and presented in newsletters and at 
meetings of the Dutch Noonan syndrome Foundation. in total, approximately 150 patients were approached, of whom 
a maximum 25% were thought to be eligible, because children and adolescents aged ,16 years, adult patients without 
social cognitive complaints, or patients who were not interested in this intervention were not eligible for participation.
1b. Number of participants from sample of eligible persons
initially, 15 patients were interested in participating in the training. Five patients were excluded due to age (,16 years) 
or low verbal intelligence. Four other patients were eligible for inclusion but did not (yet) participate, because they 
could not combine the training with current work or study obligations or because they did not respond to invitations. 
given the small number of patients who volunteered, it was not possible to allocate patients randomly to a treatment 
group and a waiting-list control group. Therefore, control participants were actively recruited at meetings of the Dutch 
Noonan Syndrome Foundation, and five patients were included in the control group. The control group did not follow 
the training at a later point in time. One patient of the control group subsequently participated in the training. No pre- 
or posttest information was obtained from this participant after the training because they had already been included in 
the control group and repeated neuropsychological assessment after participation in the training would have affected 
the results. The training was provided in two treatment groups (n=4 and n=3), which started consecutively. in sum, 
11 patients were included in this study: six in the treatment group and five in the control group.
1c. Number of participants vs aimed-at number
The aim was to include 20 patients (ten in the treatment group and ten in the control group). The recruitment 
objective was not reached.
2. Barriers and facilitators in recruitment and selection
2a. Difference in baseline characteristics between nonparticipating and participating eligible persons
No information was available regarding differences between participating and nonparticipating eligible patients. There 
were no significant differences in demographics or baseline variables between the control group and treatment group, 
although this could reflect a power problem due to the small study sample size. Because the groups could not be 
allocated randomly, a selection bias might be present, as patients with more severe social cognitive deficits may be 
more inclined to participate in the treatment group.
2b. Motivation of nonparticipating and participating eligible persons
some patients who were initially interested in the training could not make the required time investment in 
combination with current work or study activities. There also seemed to be some hesitation for participation in group 
training. Possibly, the nature of the (social) cognitive problems of patients with Ns could provide an explanation for 
these findings.
2c. Experience with recruitment and selection
although there appeared to be much interest for the social cognitive training, the number of patients that volunteered 
in the feasibility study was lower than expected.
3. Number of participants completing follow-up vs number started
3a. all participants completed the neuropsychological measures at pre- and posttest. however, not all self-report and 
proxy questionnaires were returned.
4. Barriers to and facilitators of follow-up
4a. Reasons for dropout and motivation for continued participation
There were no dropouts. all participants in the treatment group completed the training and wanted to improve their 
social cognitive functioning. Patients in both groups valued the importance of this study to increase the treatment 
options for patients with Ns and were driven to contribute.
Complex intervention 1. Quality of delivery of the interventional components
1a. Part of each component and complete intervention delivered by instructors
all three phases of the intervention (perception, interpretation, reaction) were delivered successfully. The number and 
difficulty of exercises could be adjusted flexibly to the level of social cognitive functioning of the group or to individual 
participants.
(Continued)
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Table 2 (Continued)
Process components Findings
1b. Satisfaction with delivery
all phases appeared to be feasible. it was observed that participants were inclined to spend a lot of time on sharing 
their experiences at the expense of practicing social cognitive exercises. a possible explanation for this observation 
could be that patients with Ns seldom met other patients and enjoyed exchanging experiences. however, it could also 
reflect avoidance of (possibly distressing) exercises or be the result of verbosity, due to executive difficulties. The time 
spent on psychoeducation could be shortened in favor of more (group) exercises. The training initially incorporated 
one proxy session without participants and one evaluation session with proxies and participants together. after 
evaluation of the first training group, both proxy sessions were provided in the presence of the participants.
2. Barriers and facilitators for delivery of interventional components
2a. Reasons for diverging from or applying (planned) components
The three phases of the training were all delivered, although the exercises were slightly adjusted to the level of social 
cognitive functioning of the group. Despite differences in intellectual capacities and education level, participants had 
comparable training aims and found many similarities between one another’s social cognitive difficulties.
3. Adherence to interventional components
3a. Number of sessions followed
Three participants (50%) followed all sessions. One participant missed one-and-a-half sessions due to problems with 
public transport. Two participants missed two sessions, because of work-related activities or health issues. When 
sessions were missed, participants received the information and exercises of that week by email, studied them 
independently, and had the opportunity to ask questions via email or telephone. On average, less than one session was 
missed (mean 9.08±1.02 sessions). Not all training partners attended both proxy sessions, due to the required time 
investment, work obligations, or cognitive difficulties.
3b. Intervention components (partly) followed
The participants received all three training phases.
3c. Compliance with individual recommendations
individual recommendations were followed up.
3d. Homework adherence
all participants did homework exercises, although some needed additional guidance or support. The number and 
nature of the homework exercises slightly differed each week. some patients viewed the number of exercises as 
too many. also, there seemed to be a tendency to avoid exercises with training partners. some proxies were thus 
less involved in the training than intended. adequate involvement of a training partner seemed to be supportive and 
beneficial for the participant.
4. Barriers and facilitators for adherence to interventional components
4a. Motivation for (lack of) attendance and compliance
Patients appeared motivated to attend the training. They valued the importance of the training and seemed to enjoy the 
sessions.
5. Experience of participants and instructors with interventional components
5a. Perceived benefit
All participants reported that they benefited from the training. They mentioned, eg, an increased awareness of social 
cognitive difficulties (related to NS) and the acquisition of useful strategies to improve social cognitive functioning in 
daily life. In addition to the content of the training, participants seemed to benefit from recognition of one another’s 
experiences and the support from their group members. For some participants, this training was the first time they had 
come in contact with other patients with Ns. Patients also mentioned that the training was intensive and demanding 
with regard to emotional load and time investment required. Two participants suggested more time and elaboration, 
eg, on social rules and social interaction. Furthermore, it was suggested by one participant that it be stated more clearly 
that the homework exercises could be time-consuming and to provide a contact person who patients could reach when 
they felt worse or relapsed. Three of the training partners who evaluated the training posttest felt that the participants 
benefited from the training. The training partners judged the proxy sessions as sufficient in frequency, although one 
partner mentioned that more proxy sessions were preferred. For the three other patients, no evaluative information 
was provided by their training partners. On average, general satisfaction with the training, evaluated by five participants 
in the treatment group, was judged as 8.9 (ranging from 0 to 10). satisfaction with the therapeutic relationship 7.8, 
satisfaction with aims and topics of training 7.6, and satisfaction with approach and methods 8.4.
5b. Strong and weak aspects of the interventional components (structure and content) and the total 
intervention
strong aspects of the training concerned its (small) group-based format, in which patients learned from each other’s 
experiences, increased their awareness of social cognitive difficulties, and were able to practice learned strategies. The 
training stimulated three participants for additional psychotherapy to continue practicing with the training topics.
(Continued)
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Table 2 (Continued)
Process components Findings
For two patients, information and elements from the training were incorporated into already-existing coaching or 
counseling trajectories. in addition, patients used the psychoeducation provided during the training to inform other 
people (eg, healthcare professionals or family members) or in cases of relapse. every 6 months, participants were 
invited to follow up evaluation-group sessions at meetings of the Dutch Noonan syndrome Foundation. if patients 
were not able to participate in this session, individual (telephone) contact was offered. Besides the small sample, a weak 
aspect of the training may be the slight imbalance between time spent on psychoeducation and discussion of social 
cognitive complaints and the amount of practice time. More concise and practical psychoeducation in combination with 
additional exercises may be helpful. also, some training partners were less involved in the training than intended.
Evaluation data 1. Outcome measure: coverage of interventional components
1a. Average number of outcomes per component
Primary outcome measures covered all three phases of social cognition that were addressed in the training: perception 
(emotion recognition Task and alexithymia questionnaire), interpretation (social perception task, theory-of-mind task, 
and alexithymia questionnaire), and reaction (questionnaire of social behavioral problems and alexithymia). The five 
secondary outcome measures concerned nonsocial cognition (speed of information processing, inhibition, and planning), 
psychopathology ([social] anxiety and mood problems), quality of life, and self-efficacy.
2. Completeness of data collection
2a. Number and characteristics of missing data
Neuropsychological test data were complete. With regard to the questionnaires, for one patient in the treatment group 
the BVaQ and DeX-sc were missing posttest, while the siB was missing both pre- and posttest in this individual. For 
one control participant the BVaQ, DeX-sc, and siB were missing. One individual in the treatment group missed one 
page of the questionnaire book, which was replaced with the pretest scores. in addition, there were nine incidental 
missing data points (five in the treatment group and four in the control group): six at pretest and three at posttest. Most 
missing data were on the BVaQ, siB, and DeX-sc. if it was not possible to recontact participants, incidental missing 
data points were replaced with the score at pre- or posttest (depending on which score was missing) or with the 
average score on other items of that questionnaire. When two answers were given, the average score was calculated.
3. Barriers to and facilitators of data collection
3a. Feasibility of outcome measures
The test battery lasted approximately 2 hours but was not considered too long by participants. Questionnaires were 
filled out mostly at home, which possibly led to a lower response rate. Three participants in the treatment group 
reported trouble with some of the questionnaires, and one received help from a friend. One proxy had difficulty filling 
out the questionnaires and thus did not complete the posttest.
3b. Reasons data were missing
Reasons for attrition in returning the questionnaires at posttest were difficulty with completing the questionnaires, lack 
of supervision while filling out the questionnaires, psychosocial problems, and unfortunate practical complications with 
mail-order services.
3c. Reasons participants were excluded from analysis
There were no participants excluded from analyses for reasons other than missing data. With regard to heterogeneity 
in patient characteristics in this sample, outliers could be present. however, for the purpose of this feasibility study, 
all data were included.
4. Comparison of qualitative and quantitative effectiveness data
The perceived benefit by patients and training partners was not reflected by the quantitative data. Finding no significant 
improvement on primary or secondary outcome measures may be the result of a power problem due to the small 
sample. Furthermore, it is possible that some tests in the current battery were not able to detect differences 
adequately between pre- and posttest.
Abbreviations: BVaQ, Bermond–Vorst alexithymia Questionnaire; DeX-sc, Dysexecutive Questionnaire – social conventions; Ns, Noonan syndrome; siB, scale for 
interpersonal Behavior.
there appeared to be no significant differences between the 
treatment group and the control group with regard to NART 
IQ (treatment median 78, control median 85, U=13, z=-0.37, 
r=-0.11; P=0.76), and age (treatment median 50 years, con-
trol median 40 years, U=7.50, z=-1.38, r=-0.42; P=0.19), 
although the effect size for age was medium–large.
Five patients in the treatment group reported previous psy-
chological problems (mood problems, anxiety, stress-related 
psychological complaints, alcohol abuse), and three had 
current psychological complaints (mainly mood problems). 
Two patients were still receiving psychosocial counseling, 
which did not focus on improving social cognition. All 
participants in the control group had received psychological 
treatment once in their lives for anxiety and compulsions, 
posttraumatic stress disorder, suicidal ideation, attention 
deficit/hyperactivity disorder, or a history of being bullied. 
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Two participants in the control group reported current psy-
chological problems, and one was still receiving psychologi-
cal and psychiatric treatment, not aimed at reducing social 
cognitive problems, at another mental healthcare facility.
Baseline measures
The Dutch version of the NART was administered at baseline 
as an estimate of intellectual functioning.36
Primary outcome measures
emotion recognition
The Emotion Recognition Task (ERT) was used as a measure 
of facial emotion recognition.38 The ERT is a computer task 
in which participants are presented with dynamic images of 
the faces of four actors expressing the six basic emotional 
expressions: anger, disgust, fear, happiness, sadness, and 
surprise. A computer program enables real-time interactive 
morphing between a neutral expression and the emotional 
expression in four intensities (40%, 60%, 80%, and 100%).38 
After each video clip, the participant is asked to choose 
among the six emotions, displayed as buttons on the test 
computer. Performance is defined by the total number of 
correctly identified emotional expressions. Scores range from 
0 to 96, and higher scores represent better facial emotion 
recognition. The ERT has been validated in a wide range of 
clinical groups and normative data of healthy participants 
are available.38
Theory of mind
Two subtests of the short Dutch version of The Awareness of 
Social Inference Test (TASIT-NL) were used as measures of 
ToM.39,40 A combined score of the subtests social inference – 
minimal (SI-M) and social inference – enriched (SI-E) was 
used, because these subtests measure aspects of ToM, while 
the first subtest – the emotion-evaluation test – addresses 
emotion recognition.40 The TASIT-NL is the only ToM test 
that uses videos of actual persons in familiar social situations. 
Subtest SI-M includes nine videos with three sincere, three 
sarcastic, and three paradoxical sarcastic scenes. After each 
video, the participant has to answer four questions about what 
the actor was doing, saying, thinking, and feeling. Subtest 
SI-E consists of eight other videos (four lies, four sarcastic 
scenes) with additional contextual cues to assist the under-
standing of the situation. After each video, the participant has 
to answer the same four questions (do, say, think, feel). The 
combined score for the two subtests ranges from 0 to 68, with 
higher scores reflecting better ToM abilities. The TASIT-NL 
has two parallel forms: form A (used at pretest) and form B 
(at posttest). Although some differences were found between 
the two forms regarding difficulty at item level and presence 
of a sequence effect for subtest SI-M (lower performance 
on form B when participants first completed form A), no 
differences were found between forms A and B on subtest 
total scores and overall score, indicating that both forms are 
comparable. Overall performance on the alternate forms was 
correlated moderately (r=0.45).40
social perception
The social interpretation test (SIT) was used as a measure of 
social perception.41 The SIT consists of a colored drawing 
depicting a social situation (an accident and reactions of 
people in the street). Nine open questions are asked to the 
participant, such as “Can you tell me something about the 
picture?”; “Do you think there is something striking or 
strange in the picture?”; and “How are these people involved 
in the situation?”. The SIT contains a scoring system with 24 
statements, and correct answers are scored as 1 point. The 
SIT has a parallel version using a different yet comparable 
drawing. Form A was used at pretest and form B at posttest. 
A maximum score of 21 could be obtained, because only 
those statements that were thought to be plausible analogies 
between the two forms were used.41 Performance on the two 
forms was highly correlated (r=0.82).41
alexithymia
The Bermond–Vorst Alexithymia Questionnaire (BVAQ) 
was administered to measure alexithymia.42 This question-
naire consists of 40 items, which are rated on a 5-point Likert 
scale. The BVAQ includes five factor-based subscales (emo-
tionalizing, fantasizing, identifying, analyzing, and verbal-
izing), and two higher-order scales (affective and cognitive 
dimensions). The total score on the BVAQ (40–200) was used 
in this study, with higher scores reflecting higher levels of 
alexithymia. Patients in both groups completed a self-report 
version of this questionnaire. In addition, for participants in 
the treatment group, a partner or other person close to the 
patient (ie, their training partner) was asked to complete a 
proxy version of this list constructed by the researchers. The 
reliability and validity of the self-report version of the BVAQ 
are acceptable, and normative data of healthy participants 
are available.42,43
social behavioral problems
Based on the factor-analysis study of Bodenburg and 
Dopslaff,44 a subscale of the Dysexecutive Questionnaire 
was calculated measuring social conventions and the ability 
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to incorporate social interaction in one’s own behavior 
(DEX-SC).45 The subscale consists of four items. Total scores 
range from 0 to 16, with higher scores reflecting more social 
behavioral problems. Patients in the treatment and control 
groups completed the self-report version of the DEX-SC, 
and for participants in the treatment group a proxy version 
of this list was completed by a partner or other person close 
to the patient (ie, their training partner).
secondary outcome measures
speed of information processing and inhibition
The Stroop color-word test (CWT) was assessed to measure 
processing speed and response inhibition.46,47 The average 
time to complete the first two conditions is used as a measure 
of mental speed. A ratio score (completion time on third 
condition divided by the average time on conditions 1 and 2) 
was calculated to reflect the ability to inhibit an automatic 
response. Lower ratio scores reflect better inhibition. The reli-
ability of the Stroop CWT is considered good and construct 
validity sufficient.48
Planning
An adapted version of the modified six-elements test (MSET), 
a subtest of the behavioral assessment of the dysexecutive-
syndrome battery, was used to measure planning abilities.45,49 
The adapted MSET was used, because it has two parallel 
forms (version 1 was used at pretest and version 2 at posttest), 
reduced ceiling effects in mildly impaired individuals, and a 
more differentiated scoring system.50 In the adapted MSET, 
the original dictation subtask has been replaced with a sort-
ing task. The other subtasks include arithmetic (version 1), 
categorizing pictures (version 1), picture naming (version 2), 
and categorizing words (version 2). The test procedure of 
the adapted MSET is comparable to the original task. In this 
study, the scoring method of the adapted MSET ([time of 
longest subtasks – time of shortest subtasks]/[number of 
executed tasks – rule breaks]) was used.50 Lower adapted 
MSET scores indicate better planning performance. Norma-
tive data of healthy participants are available.50
social distress
The Scale for Interpersonal Behavior (SIB) was used to 
reflect engagement in social behavior and related distress.51 
The SIB includes 50 items reflecting social behavior, of 
which the participant has to evaluate (on two separate 5-point 
scales) the probability of engaging in this behavior (perfor-
mance scale) and the level of stress it evokes (distress scale). 
For the purpose of this study, only the distress scale was used. 
Higher scores reflect higher levels of social distress. The 
construct validity and reliability of the SIB are considered 
good and criterion validity sufficient.52 Normative data of 
healthy participants are available.77
anxiety and depression
The Dutch version of the Symptom Checklist 90 – revised 
(SCL-90-R) was used to measure general psychological 
complaints.53 The questionnaire consists of 90 items, which 
are rated on a 5-point scale. For the purpose of this study, only 
the depression (16 items) and anxiety (10 items) subscales 
were administered. Higher scores reflect a higher level of 
complaints. The reliability, construct validity, and criterion 
validity of the SCL-90-R are considered good.54 Normative 
data of healthy participants are available.53
Quality of life and self-efficacy
Two short self-report questionnaires of quality of life (three 
items) and self-efficacy regarding social cognitive function-
ing (eight items) were administered. These questionnaires 
were developed by the authors, based on items of the Dutch 
version of the Acceptance and Action Questionnaire and the 
Lancashire Quality of Life Questionnaire,55,56 and adjusted 
to the NS population. Higher scores on these questionnaires 
reflect a higher level of quality of life or self-efficacy.
Data analyses
Pretest scores on the primary and secondary outcome mea-
sures of the treatment and control groups were compared 
using a Mann–Whitney U tests. Wilcoxon signed-rank tests 
were performed to investigate pre- vs posttest differences in 
the treatment and control groups. Effect sizes were calculated 
manually using the equation: r=z/(√n).57,58 Analyses were 
performed with SPSS version 23.0.0.0.
For tests for which normative data of healthy participants 
were available and no adjusted scores were used in the current 
study (ie, ERT, BVAQ, MSET, SIB, SCL-90-R), individual 
test scores were classified as low (,-2 SD), below average 
(-1.5 to -2 SD), above average (1.5–2 SD), or high (.2 SD). 
A process evaluation (ie, a structured exploration of each 
process of an intervention) was added, as it can provide 
valuable information regarding the understanding of both 
positive and negative outcome results.59 In the current study, 
the process evaluation was structured into three components, 
as suggested by Reelick et al:59 success rate of recruitment and 
quality of study population, quality of execution of complex 
intervention, and process of acquisition of evaluation data.
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Results
Baseline testing
The results of the treatment group and control group at 
baseline are displayed in Table 3. On primary and secondary 
outcome measures, no significant differences were found 
between the groups, even though medium–large effect 
sizes were present for differences on the ERT, DEX-SC, 
quality of life, self-efficacy, SCL-90-R – anxiety, and Stroop 
CWT – inhibition.
Compared to normative data, one patient in the treatment 
group had below-average performance on the ERT and one 
patient in this group performed at a low level. Two patients 
had above-average alexithymia levels on the BVAQ and 
two patients had high levels. For two patients, proxy reports 
showed above-average levels of alexithymia, while for two 
patients high levels of alexithymia were reported by proxies. 
Two patients reported high levels of depression on the 
SCL-90-R. In the control group, two patients reported high 
levels of alexithymia. Two patients in this group reported 
high levels of depression on the SCL-90-R and one patient 
reported high levels of anxiety on the same questionnaire. 
One patient reported an above-average level of social distress 
on the SIB and one patient reported high levels of social 
distress. One patient showed a low planning performance on 
the MSET. The classifications are displayed in Tables 4–7.
Pretest vs posttest
There appeared to be no significant differences on primary 
outcome measures between pre- and posttest scores in the 
treatment group or the control group (Tables 4 and 5). 
However, the effect size of improvement on the ERT was 
medium–large in the treatment group, while it was only 
small–medium in the control group.
Regarding secondary outcome measures, there were no 
significant differences between pre- and posttest scores in 
either group, although improvement on the adapted MSET 
in the treatment group and the faster performance of the 
control group on Stroop CWT processing speed almost 
reached significance and effect sizes were large (Tables 6 
and 7). Despite the lack of significant results, the effect size 
of the improvement in inhibition scores on the Stroop CWT 
in the treatment group was medium–large, while decreased 
performance on this task in the control group showed a large 
effect. Furthermore, large effects were found in the control 
group with regard to the (nonsignificant) improvement in 
planning abilities on the adapted MSET and the decrease in 
anxiety on the SCL-90-R, while a medium effect was found 
for the decrease in depression. Since both groups showed 
a (medium to) large effect on improvement on the adapted 
MSET, this most likely reflected a practice effect.
Process evaluation
In Table 2, detailed information regarding the process 
evaluation is displayed. The results of the process analysis 
regarding selection of the study population showed that 
the number of included patients was smaller than intended. 
It is hypothesized that the lower inclusion may have been 
influenced by the nature of the (social) cognitive deficits 
Table 3 Baseline performance of treatment group compared to control group
Outcome measures Treatmenta 
(n=6)
Controla  
(n=5)
U z P-value rb
erT 47 52 9 -1.10 0.31 -0.33
TasiT-Nl 49 52 11 -0.74 0.50 -0.22
siT 12.5 13 11.5 -0.65 0.54 -0.20
BVaQ 119 104 12 -0.55 0.62 -0.17
DeX-sc 9 7 9.5 -1.02 0.37 -0.31
stroop cWT processing speed 55.5 48.5 12 -0.55 0.66 -0.17
stroop cWT inhibition 1.75 1.59 6 -1.64 0.13 -0.49
adapted MseT 18.5 15 11.5 -0.64 0.57 -0.19
siB distress 109 117 11 -0.31 0.84 -0.09
scl-90-r anxiety 17.5 12 9 -1.10 0.32 -0.33
scl-90-r depression 28 22 11 -0.73 0.51 -0.22
Quality of life 12.5 16 9 -1.11 0.33 -0.33
Self-efficacy 36 39 9.5 -1.01 0.35 -0.30
Note: aMedians; beffect size.
Abbreviations: BVaQ, Bermond -Vorst alexithymia Questionnaire; cWT, color-word test; DeX-sc, Dysexecutive Questionnaire – social conventions; erT, emotion 
Recognition Task; MSET, modified six-elements test; SCL-90-R, Symptom Checklist 90, revised; SIB, Scale for Interpersonal Behavior; SIT, social interpretation test; TASIT-
Nl, The awareness of social inference Test (Dutch version).
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issues (eg, time investment). In addition to the content of the 
training, participants also benefited from the support they felt 
from their group members. It was observed that patients were 
inclined to spend much time on sharing their experiences in a 
detailed manner during the sessions, at the expense of training 
time. Supposedly, most patients with NS seldom meet other 
patients and greatly valued the recognition of one another’s 
experiences and (social cognitive) problems. Alternatively, 
the observed tendency to share experiences extensively may 
reflect avoidance of (potentially distressing) exercises during 
the training or may be the result of verbosity, caused by 
in patients with NS. There were no dropouts among the 
included patients.
With regard to the evaluation of the intervention itself, the 
results of the process evaluation indicated that all three phases 
of the training were delivered successfully. All participants 
reported benefiting from the training. Increased awareness of 
social cognitive difficulties (related to NS) and the acquisition 
of useful strategies to improve social cognitive functioning 
were mentioned most frequently, though participants also 
reported that they had experienced the training as intensive 
and demanding in terms of the emotional load and practical 
Table 4 results of treatment-group patients on primary outcome measures at pre- and posttest
Patient number ERT TASIT-NL SIT BVAQa DEX-SCa BVAQ proxya DEX-SC 
proxya
Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post
1 51 51 56 56 12 11 93 119 9 11 113b 111 10 13
2 31c 45 47 52 9 10 117b 127 10 7 150c 150 14 8
3 41b 55 49 46 9 10 122c – 9 – 100 115 8 9
4 43 39 43 42 13 11 121b 127 7 9 124c – 7 –
5 61 59 60 55 15 16 146c 127 10 12 108 102 11 9
6 51 61 49 45 16 16 103 90 8 9 118b 121 13 11
Median 47.00 53.00 49.00 49.00 12.50 11.00 117.00 127.00 9.00 9.00 113.00 115.00 11.00 9.00
interquartile range 15.00 16.00 11.00 11.00 6.25 6.00 35.50 22.50 2.50 3.50 30.00 29.00 4.50 3.50
Te 3.00 4.50 7.50 7.00 5.00 4.00 5.00
z -1.22 -0.81 0 -0.14 -0.69 -0.37 -0.68
P-value 0.31 0.50 1.00 1.00 0.56 0.88 0.63
rd -0.35 -0.23 0 -0.04 -0.22 -0.12 -0.22
Note: aMedian, interquartile range, and test statistics calculated for five patients; bbelow/above-average performance at pretest; clow/high performance at pretest; deffect size; 
eTest statistic of Wilcoxon signed-rank test reflecting the smallest sum of ranks.
Abbreviations: BVaQ, Bermond–Vorst alexithymia Questionnaire; DeX-sc, Dysexecutive Questionnaire – social conventions; erT, emotion recognition Task; siT, 
social interpretation test; TasiT-Nl, The awareness of social inference Test (Dutch version).
Table 5 results of control-group patients on primary outcome measures at pre- and posttest
Patient number ERT TASIT-NL SIT BVAQa DEX-SCa
Pre Post Pre Post Pre Post Pre Post Pre Post
1 45 27 45 44 13 9 124b 144 9 6
2 56 61 52 59 13 11 104 – 6 –
3 52 49 58 49 11 11 89 90 12 12
4 47 53 52 60 14 16 126b 105 7 8
5 59 65 58 54 16 16 89 91 5 5
Median 52.00 53.00 52.00 54.00 13.00 11.00 106.50 98.00 8.00 7.00
interquartile range 11.50 25.00 9.50 13.00 3.00 6.00 36.50 44.00 5.75 5.75
Td 6.00 7.00 1.50 4.00 1.00
z -0.41 -0.14 -0.82 -0.37 -0.45
P-value 0.75 1.00 0.75 0.88 1.00
rc -0.13 -0.04 -0.26 -0.13 -0.16
Note: aMedian, interquartile range, and test statistics calculated for four patients; blow/high performance at pretest; ceffect size; dTest statistic of Wilcoxon signed-rank test 
reflecting the smallest sum of ranks.
Abbreviations: BVaQ, Bermond–Vorst alexithymia Questionnaire; DeX-sc, Dysexecutive Questionnaire – social conventions; erT, emotion recognition Task; siT, 
social interpretation test; TasiT-Nl, The awareness of social inference Test (Dutch version).
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difficulties in executive functioning. Although homework 
exercises were performed satisfactorily, participants tended 
to avoid exercises with their training partners. Patients who 
involved their training partners seemed to profit from the 
participation of their proxies. Three of the five training part-
ners who shared their experiences after training reported that 
the participants benefited from the training in their opinion.
Lastly, the results of the process evaluation of outcome 
measures showed that the neuropsychological test data were 
complete, but that not all questionnaires were returned. This 
could suggest a difficulty with completing the questionnaires. 
The missing data may have influenced the findings in this 
study, because conservative methods were used to compen-
sate for these. The perceived benefit by patients and their 
training partners was not reflected by the quantitative data.
Discussion
In the present study, applicability and feasibility of a new 
social cognitive training for adult patients with NS was 
evaluated. The training appeared feasible, and promising 
results were found with regard to enhancement of emotion 
recognition, although the overall effectiveness of the training 
could not be quantified, due to the small sample.
With regard to baseline measures, no significant differ-
ences were found between the treatment and control groups. 
However, several outcome measures showed medium–large 
effect sizes when comparing the two groups, which may 
suggest that meaningful differences between the treat-
ment and control groups on these variables could not be 
demonstrated due to a power problem. Baseline variables 
that potentially differed were higher age, poorer emotion 
recognition, lower levels of quality of life and self-efficacy, 
more social behavioral problems, more anxiety, and a worse 
inhibition score in the treatment group in comparison to the 
control group. Possible baseline differences between the 
groups might have resulted from the inclusion of patients 
with subjective or objective social cognitive impairments in 
the treatment group.
Within each group, no significant differences between 
pre- and posttest were found for primary outcome measures. 
However, the medium–large effect size of the pre- vs posttest-
difference on ERT in the treatment group compared to the 
small–medium effect sizes in the control group may indicate 
that the effects on emotion recognition were stronger in the 
treatment group. An improvement in emotion recognition 
was expected, because it has been a consistent finding in 
other social cognitive interventions.21 Finding no significant 
improvement in the treatment group on subjective measures 
of social cognitive functioning may reflect increased aware-
ness of social cognitive difficulties. Awareness of one’s 
(social) cognitive problems can be considered an initial step 
toward behavioral change.
Regarding secondary outcome measures, no significant 
differences were found between pre- and posttest in either 
group. However, the improvement in adapted MSET scores 
in the treatment group and faster processing on the Stroop 
CWT in the control group almost reached significance. In 
addition, the medium–large effect sizes of the (nonsignifi-
cant) improvement on the Stroop CWT – inhibition in the 
treatment group and the (nonsignificant) improvement on the 
adapted MSET and SCL-90-R and (nonsignificant) decrease 
on Stroop CWT – inhibition in the control group may reflect 
differences that could not be demonstrated by the Wilcoxon 
signed-rank test due to power problems. Moreover, large 
effects were found in both groups with regard to the (non-
significant) improvement in planning abilities on the adapted 
MSET, which most likely reflected a practice effect.
The process evaluation showed that there were no drop-
outs, all three phases of the intervention were feasible, and 
patients reported benefits from the training. Strong aspects 
concerned the (small) group-based format, in which NS 
patients learned from one another’s experiences, gained more 
awareness of their social cognitive difficulties, and were able 
to practice strategies. The number of patients included in this 
study was smaller than intended, which could be related to 
the nature of the (social) cognitive deficits in patients with 
NS. Providing more information concerning the beneficial 
effects of group training and considering alternative train-
ing locations in order to reduce the time investment may 
be helpful in this regard. eHealth interventions can also 
be considered, although exercising social skills in real-life 
interaction remains necessary. The evaluation also showed 
that more time may be spent on practicing social cognitive 
skills and performing exercises and to a lesser extent on 
psychoeducation and discussion of experiences and social 
cognitive complaints. Additional exercises can be consid-
ered, focusing for instance on emotion-regulation strategies, 
task-concentration training, and elements of acceptance and 
commitment therapy, which may be helpful in diminishing 
alexithymic problems and social anxiety and in increasing 
acceptance of emotions. Furthermore, training partners were 
less involved in the training than intended, which could have 
hampered the generalization of training effects to daily life. 
The selection of appropriate training partners, their role, and 
the benefits of their involvement should be addressed more 
elaborately during both the intake procedure and the sessions 
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in which they are present. It also appeared that patients had 
some difficulty with filling out the questionnaires. Supervised 
administration of the questionnaires and the use of shorter 
instruments, eg, replacing the BVAQ with the shorter Toronto 
Alexithymia Scale 20, may be helpful in this regard.60 Fur-
thermore, a revision of the test battery is suggested. Although 
the TASIT has many benefits (ie, alternate forms and videos 
of real-life social situations) and is used frequently, the Dutch 
version is still time-consuming and its suitability for repeated 
administration is questionable.61 Other ToM tasks may be 
considered, eg, a recognition of faux pas task.62–64
Despite the fact that this is the first controlled study to 
evaluate a new social cognitive training for adult patients with 
NS, there are also some limitations. Firstly, the study sample 
was small, which has consequences for the power. Further-
more, because subjective or objective social cognitive impair-
ments were required for inclusion in the treatment group, a 
selection bias could be present, which limits the interpretation 
of pre- vs posttest results to this group. Although no baseline 
differences were found between the groups, the presence of 
several medium–large effect sizes on baseline comparisons 
may suggest that meaningful differences between the groups 
could not be demonstrated due to limited statistical power. 
Also, patients were not randomly allocated to the groups, 
and we emphasize that these preliminary findings should 
be interpreted with caution and replicated in a randomized 
controlled trial. Because only nonparametric analyses were 
performed, no interaction effects between group (treatment 
vs control) and time (pre vs post) could be explored. As a 
result of the large heterogeneity in cognitive functioning in 
the NS population, possible outliers may have influenced 
the results of the analyses. However, these effects are con-
sidered minimal, due to the use of nonparametric testing. 
Lastly, all participants in the treatment group underwent 
neuropsychological assessment at the Center of Excellence 
of Neuropsychiatry for different periods before the training 
(approximately 1–8 years). Some of the outcome measures 
in the current test battery overlapped with this neuropsycho-
logical assessment, which could have led to practice effects.
Conclusion
In conclusion, this first social cognitive training for adult 
patients with NS, based on existing evidence-based and 
best-practice social cognition and alexithymia interventions, 
has proven to be a feasible training for this population. 
Moreover, encouraging results were found with regard to the 
enhancement of emotion recognition. Based on the process 
evaluation, some alterations in the training protocol and test 
battery may be helpful in order to optimize the procedure. 
Future studies are needed using a larger sample and ran-
domized controlled design, in order to evaluate further the 
effectiveness of the training.
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